Current and Future Pharmacologic Complement Inhibitors

Hematology/Oncology Clinics of North America

Volumn 29, Issue 3, 2015, Pages 561-582

  Risitano, Antonio M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

AHUS; C3; C5; Complement therapeutics; Compstatin; Eculizumab; PNH

Indexed keywords

AMY 101; APL 2; APTAMER; ARC 1005; AVACINCAPTAD PEGOL; CDX 1135; COMPLEMENT INHIBITOR; COVERSIN; CYNRYZE; ECULIZUMAB; H 17; LAMPALIZUMAB; LFG 316; MIROCOCEPT; MUBODINA; RA 101348; SMALL INTERFERING RNA; SOBI 002; TA 106; TNT 003; TT 30; TT 32; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY; PROTEIN BINDING;

AGE RELATED MACULAR DEGENERATION; ANGIONEUROTIC EDEMA; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL TRIAL (TOPIC); COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; DENSE DEPOSIT DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOREGULATION; INTRAVASCULAR HEMOLYSIS; KIDNEY DISEASE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; DRUG EFFECTS; FORECASTING; HEMOGLOBINURIA, PAROXYSMAL; METABOLISM; PROCEDURES; TRENDS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT C5; COMPLEMENT INACTIVATING AGENTS; DRUG THERAPY; FORECASTING; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; PROTEIN BINDING;

EID: 84930039591     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.01.009     Document Type: Review

References (111)

1. Ricklin D., Hajishengallis G., Yang K., et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
2. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. JImmunol 2013, 190:3831-3838.
3. Pio R., Corrales L., Lambris J.D. The role of complement in tumor growth. Adv Exp Med Biol 2014, 772:229-262.
4. Holers V.M. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008, 223:300-316.
5. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. JImmunol 2013, 190:3839-3847.
6. Ricklin D., Lambris J.D. Progress and trends in complement therapeutics. Adv Exp Med Biol 2013, 735:1-22.
7. Lunn M., Santos C., Craig T. Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety. JBlood Med 2010, 1:163-170.
8. Risitano A.M. Paroxysmal nocturnal hemoglobinuria. Anemia 2012, 331-374. InTech, Rijeka, Croatia. D. Silverberg (Ed.).
9. Luzzatto L., Notaro R. Paroxysmal nocturnal hemoglobinuria. Blood, principles and practice of hematology 2003, 319-334. Lippincot Williams & Wilkins, Philadelphia. 2nd edition. R.I. Handin, S.E. Lux, T.P. Stossel (Eds.).
10. Parker C.J., Ware R.E. Paroxysmal nocturnal hemoglobinuria. Wintrobe's clinical hematology 2003, 1203-1221. Lippincott Williams & Wilkins, Philadelphia. 11th edition. J. Greer, J. Foerster, J. Lukens (Eds.).
11. Miyata T., Takeda J., Iida Y., et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993, 259:1318-1320.
12. Takeda J., Miyata T., Kawagoe K., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993, 73:703-711.
13. Nicholson-Weller A., Burge J., Fearon D.T., et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. JImmunol 1982, 129(1):184-189.
14. Nicholson-Weller A. Decay accelerating factor (CD55). Curr Top Microbiol Immunol 1992, 178:7-30.
15. Holguin M.H., Fredrick L.R., Bernshaw N.J., et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. JClin Invest 1989, 84:7-17.
16. Meri S., Morgan B.P., Davies A., et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990, 71(1):1-9.
17. Rother R.P., Rollins S.A., Mojcik C.F., et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
18. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. NEngl J Med 2006, 355:1233-1243.
19. Brodsky R.A., Young N.S., Antonioli E., et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008, 114:1840-1847.
20. Hillmen P., Muus P., Duhrsen U., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007, 110:4123-4128.
21. Rother R.P., Bell L., Hillmen P., et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005, 293:1653-1662.
22. Helley D., de Latour R.P., Porcher R., French Society of Hematology, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010, 95:574-581.
23. Weitz I.C., Razavi P., Rochanda L., et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res 2012, 130(3):361-368.
24. Kelly R.J., Hill A., Arnold L.M., et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011, 117:6786-6792.
25. Risitano A.M., Notaro R., Marando L., et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009, 113:4094-4100.
26. Hill A., Rother R.P., Arnold L., et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010, 95:567-573.
27. Marotta S., Giagnuolo G., Basile S., et al. Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. JHematol Thromb Dis 2014, 2(1):128.
28. Hillmen P., Muus P., Roth A., et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013, 162(1):62-73.
29. Nishimura J., Yamamoto M., Hayashi S., et al. Genetic variants in C5 and poor response to eculizumab. NEngl J Med 2014, 370(7):632-639.
30. Luzzatto L., Risitano A.M., Notaro R. Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica 2010, 95(4):523-526.
31. Risitano A.M., Marando L., Seneca E., et al. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood 2008, 112(2):449-451.
32. Risitano A.M., Notaro R., Luzzatto L., et al. Paroxysmal nocturnal hemoglobinuria-hemolysis before and after eculizumab. NEngl J Med 2010, 363(23):2270-2272.
33. Rondelli T., Risitano A.M., Peffault de Latour L.R., et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 2014, 99(2):262-266.
34. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. NEngl J Med 2009, 361:1676-1687.
35. Loirat C., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6:60-89.
36. Kavanagh D., Richards A., Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008, 59:293-309.
37. Kavanagh D., Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431-2442.
38. Fan X., Yoshida Y., Honda S., et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol 2013, 54(2):238-246.
39. Fremeaux-Bacchi V., Fakhouri F., Garnier A., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8(4):554-562.
40. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. NEngl J Med 2013, 368(23):2169-2181.
41. Cataland S.R., Wu H.M. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014, 123(16):2478-2484.
42. Zuber J., Fakhouri F., Roumenina L.T., French Study Group for aHUS/C3G, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8(11):643-657.
43. Orth-Höller D., Riedl M., Würzner R. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside. EMBO Mol Med 2011, 3:617-619.
44. Trachtman H., Austin C., Lewinski M., et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012, 8(11):658-669.
45. Neff A.T. Autoimmune hemolytic anemias. Wintrobe's clinical hematology 2003, 1157-1182. Lippincott Williams & Wilkins, Philadelphia. 11th edition. J. Greer, J. Foerster, J.N. Lukens (Eds.).
46. Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011, 153(3):309-317.
47. Swiecicki P.L., Hegerova L.T., Gertz M.A. Cold agglutinin disease. Blood 2013, 122(7):1114-1121.
48. Roth A., Huttmann A., Rother R.P., et al. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009, 113:3885-3886.
49. Roth A., Duhrsen U. Cold agglutinin disease. Eur J Haematol 2010, 84:91.
50. Parker C.J. Mechanisms of immune destruction of erythrocytes. Wintrobe's clinical hematology 2003, 1139-1155. Lippincott Williams & Wilkins, Philadelphia. 11th edition. J. Greer, J. Foerster, J.N. Lukens (Eds.).
51. Bommer M., Höchsmann B., Flegel W., et al. Successful treatment of complement mediated refractory hemolysis associated with cold and warm autoantibodies using eculizumab. Haematologica 2011, 94(Suppl 2):241. [abstract: 0593].
52. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed June 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01624636.
53. Adienne Pharma & Biotech. 2014. Available at: Accessed April 5, 2015. http://www.adienne.com/en/rd/pipeline/mubodina%ae.html.
54. Marzari R., Sblattero D., Macor P., et al. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: invitro and invivo studies. Eur J Immunol 2002, 32(10):2773-2782.
55. Woodruff T.M., Nandakumar K.S., Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011, 48(14):1631-1642.
56. Macor P., Durigutto P., De Maso L., et al. Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum 2012, 64(8):2559-2567.
57. Nunn M.A., Sharma A., Paesen G.C., et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. JImmunol 2005, 174(4):2084-2091.
58. Roversi P., Lissina O., Johnson S., et al. The structure of OMCI, a novel lipocalin inhibitor of the complement system. JMol Biol 2007, 369(3):784-793.
59. Barratt-Due A., Thorgersen E.B., Lindstad J.K., et al. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. JImmunol 2011, 187(9):4913-4919.
60. Weston-Davies WH, Westwood JP, Nunn M, etal. Phase I clinical trial of coversin, a novel complement C5 and LTB4 inhibitor. Paper presented at: 7th International Conference on Complement Therapeutics. Olympia, June 6-11, 2014. Aegean Conferences 82, abs 31.
61. Cox J.C., Rajendran M., Riedel T., et al. Automated acquisition of aptamer sequences. Comb Chem High Throughput Screen 2002, 5(4):289-299.
62. Leung E., Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol 2013, 6(5):565-579.
63. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed November 5, 2013. http://clinicaltrials.gov/ct2/show/NCT00950638.
64. Drolet DW, Zhang C, O'Connell DJ, etal. SOMAmer inhibitors of the complement system. Paper presented at: 7th International Conference on Complement Therapeutics. Olympia, June 6-11, 2014. Aegean Conferences 82, abs 23.
65. Feldwisch J., Tolmachev V. Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol 2012, 899:103-126.
66. Strömberg P. Introducing SOBI002, a small Affibody-ABD fusion protein targeting complement component C5. Paper presented at: 7th International Conference on Complement Therapeutics. Olympia, June 6-11, 2014. Aegean Conferences 82, abs 30.
67. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed November 7, 2014. http://clinicaltrials.gov/ct2/show/NCT02083666.
68. Josephson K., Ricardo A., Szostak J.W. mRNA display: from basic principles to macrocycle drug discovery. Drug Discov Today 2014, 19(4):388-399.
69. Borodovsky A., Yucius K., Sprague A., et al. Development of RNAi therapeutics targeting the complement pathway. Blood 2013, 122(21):2471.
70. Lee M., Narayanan S., McGeer E.G., et al. Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia. PLoS One 2014, 9(1):e87316.
71. Sahu A., Kay B.K., Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. JImmunol 1996, 157(2):884-891.
72. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008, 632:273-292.
73. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed March 16, 2010. http://clinicaltrials.gov/ct2/show/NCT00473928.
74. Qu H., Magotti P., Ricklin D., et al. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol 2011, 48(4):481-489.
75. Qu H., Ricklin D., Bai H., et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2013, 218(4):496-505.
76. Magotti P., Ricklin D., Qu H., et al. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. JMol Recognit 2009, 22(6):495-505.
77. Risitano A.M., Ricklin D., Huang Y., et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123(13):2094-2101.
78. Kaudlay P., Hua H., He G., et al. Red cell complement loading in PNH patients on eculizumab is associated with a C3 polymorphism which influences C3 function, predicts for increased extravascular hemolysis and provides a rationale for C3 inhibition. Blood 2013, 122(21):2466.
79. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed November 25, 2014. http://clinicaltrials.gov/ct2/show/NCT02264639.
80. Lindorfer M.A., Pawluczkowycz A.W., Peek E.M., et al. Anovel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010, 115(11):2283-2291.
81. Paixao-Cavalcante D., Torreira E., Lindorfer M.A., et al. Ahumanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. JImmunol 2014, 192(10):4844-4851.
82. Taube C., Thurman J.M., Takeda K., et al. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci USA 2006, 103(21):8084-8089.
83. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed April 1, 2015. http://clinicaltrials.gov/ct2/show/NCT01602120.
84. Bansal R. Novelmed therapeutics. 2013. Anti-properdin antibodies. US Patent 8435512, 5 July 2013. Available at: https://www.google.com/patents/US20140186348.
85. Novelmed therapeutics. Available at: Accessed April 5, 2015. http://www.novelmed.com/ProductPipeline/ParoxysmalNocturnalHemoglobinuria(PNH).aspx.
86. Altmann E, Hommel U, Lorthiois EL, etal. Novartis Ag. Indole compounds or analogs thereof as complement factor D inhibitors useful for the treatment of age-related macular degeneration and their preparation. From PCT Int. Appl.,WO 2012093101. 2012. Available at: Accessed July 12, 2012. http://www.google.com/patents/WO2012093101A1?cl=en%26hl=it.
87. Dechantsreiter MA, Grob JE, Mac Sweeney A, etal. Novartis Ag. Preparation of quinazoline compounds as modulators of the complement alternative pathway for treating macular degeneration, diabetic retinopathy, and other diseases. From PCT Int. Appl., WO 2013192345. 2013. Available at: Accessed December 27, 2013. http://www.google.com.ar/patents/WO2013192345A1?cl=en%26hl=it.
88. Shi J., Rose E.L., Singh A., et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014, 123(26):4015-4022.
89. Scwaeble WJ. The utility of lectin pathway inhibitors as modulators if inflammatory, thrombotic and haemolytic diseases. Paper presented at: 7th International Conference on Complement Therapeutics. Olympia, June 6-11, 2014. Aegean Conferences 82, abs 25.
90. DeZern A.E., Uknis M., Yuan X., et al. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Exp Hematol 2014, 42(10):857-861.e1.
91. Whaley K., Ruddy S. Modulation of the alternative complement pathway by β1H globulin. JExp Med 1976, 144:1147-1163.
92. Fridkis-Hareli M., Storek M., Mazsaroff I., et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011, 118(17):4705-4713.
93. Risitano A.M., Notaro R., Pascariello C., et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012, 119(26):6307-6316.
94. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed May 21, 2014. http://clinicaltrials.gov/ct2/show/NCT01335165.
95. Schmidt C.Q., Bai H., Lin Z., et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. JImmunol 2013, 190(11):5712-5721.
96. Hebecker M., Alba-Domínguez M., Roumenina L.T., et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. JImmunol 2013, 191(2):912-921.
97. Qiao Q., Teng X., Wang N., et al. Anovel CRIg-targeted complement inhibitor protects cells from complement damage. FASEB J 2014, 28:4986-4999.
98. Khera R., Das N. Complement receptor 1: disease associations and therapeutic implications. Mol Immunol 2009, 46(5):761-772.
99. Ross G.D., Lambris J.D., Cain J.A., et al. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. JImmunol 1982, 129(5):2051-2060.
100. Medof M.E., Nussenzweig V. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. JExp Med 1984, 159(6):1669-1685.
101. Iida K., Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. JExp Med 1981, 153(5):1138-1150.
102. Pratt J.R., Hibbs M.J., Laver A.J., et al. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996, 149(6):2055-2066.
103. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: Accessed March 6, 2014. http://clinicaltrials.gov/ct2/show/NCT01791686.
104. Zhang Y., Nester C.M., Holanda D.G., et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. JAm Soc Nephrol 2013, 24(11):1820-1829.
105. Smith RJ, Xiao H, Nester CM, etal. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. Paper presented at: 7th International Conference on Complement Therapeutics, Olympia. June 6-11, 2014. Aegean Conferences 82, abs 37.
106. Souza D.G., Esser D., Bradford R., et al. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 2005, 145(8):1027-1034.
107. Smith R.A. Membrane-targeted complement inhibitors. Mol Immunol 2012, 38:249-255.
108. Patel H., Smith R.A., Sacks S.H., et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. JAm Soc Nephrol 2006, 17(4):1102-1111.
109. Sacks S., Karegli J., Farrar C.A., et al. Targeting complement at the time of transplantation. Adv Exp Med Biol 2013, 735:247-255.
110. International Standard randomised controlled trial number register. 2014. Available at: Accessed August 3, 2012. http://www.controlled-trials.com/ISRCTN49958194.
111. Holers M, Banda N, Mehta G, etal. The human complement receptor 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertase, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity. XXIV International Complement Workshop. Chania, October 10-5, 2012: abs #230.